

AlloMek Therapeutics LLC

Uday Khire, Ph.D. MBA

CO-founder and CEO

Cell: (203) 231.3060

www.allomek.com

Email: ukhire@allomek.com



Industry: Pharmaceutical

Management:

Uday Khire, Ph.D. MBA

Co-Founder and CEO

Barry Hart, Ph.D.

Project Manager

Howard Worman, MD

Chair, SAB board

Josep Brugada, MD, Ph.D.

SAB Board

Number of Employees: 1

Current Investors

- Connecticut Innovations
- Fundación Andreas Marcio
- STTR

Legal:

- Evan Kipperman,
Wiggin and Dana

IP:

- David Ladner
Ladner Patent Management

Executive Summary: AlloMek, founded in 2011, is a privately held orphan disease-focused company, developing therapeutics for a catastrophic cardiomyopathy (based on discovery by Dr. Worman's group at Columbia University) and congenital muscular disease for which there are no disease-modifying treatments, caused by LMNA genetic mutations (laminopathies). In parallel, the company is developing therapeutics for Neurofibromatosis Type 1. AlloMek's lead compound, CIP-137401, is a unique, proprietary, macrocyclic small molecule MEK kinase inhibitor, with potency and safety advantage. It has demonstrated powerful proof of concept (POC) in a well-established mouse model of Emery-Dreifuss muscular dystrophy caused by LMNA gene mutations. CIP-137401 can potentially be used as a single agent and in combination with other treatment options to enhance clinical response.

Company History: AlloMek Therapeutics was founded in 2011 based on discovery of potent macrocyclic inhibitors of MEK kinase. The company was initially funded by Connecticut Innovations and then later won STTR award as well as funding from foundation related to laminopathies.

Market Opportunity / Unmet Need: The both rare diseases we targeting are devastating diseases with no treatment options currently available, clearly unmet need.

Commercial / Technical Milestones: The company's lead compound **CIP-137401** has completed IND enabling toxicology studies

Intellectual Property: The patent covering composition of matter has been issued in major markets